 |
|
|
|
|
|
|
|
 |
Results for 'Drug & Market Development' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
New Drug Discovery and Development
|
November 2006 |
£53 |
74 % |
Radiotracers in Drug Development
|
March 2006 |
£90 |
74 % |
Part 11 and Drug Development
A Q&A Reference Guide (March, 2004)
|
March 2004 |
£15 |
74 % |
Generic Drug Product Development
Bioequivalence
|
June 2007 |
£115 |
73 % |
Generic Drug Product Development: Specialty
Drug Products
|
June 2007 |
£115 |
72 % |
Information Management for Compliance in Drug Development
|
October 2005 |
£2500 |
72 % |
Translational Medicine - Drug Development Transformed? (Market Focus)
Drug Development Transformed? (Market Focus)
|
February 2007 |
£947 |
70 % |
RNAi Therapeutics
Challenges in Drug Development and Delivery
|
November 2005 |
£1945 |
50.4 % |
Changing Innovation in the Pharmaceutical Industry
Globalization and New Ways of Drug Development
|
July 2000 |
£64 |
50.4 % |
Companion Diagnostics in Personalized Medicine and Cancer Therapy
|
April 2008 |
£1715 |
50 % |
Innovations in Bioinformatics
Emerging Tools for Drug Discovery and Development
|
January 2008 |
£1995 |
49.7 % |
The Outlook For RNAi
Accelerating drug discovery and the development of RNAi therapeutics
|
January 2005 |
£1495 |
49 % |
Protein Drug Delivery: Penetrating a Growth Market
|
March 2005 |
£4000 |
49 % |
The Future of Systems Biology
Emerging technologies and their impact on drug discovery, development and diagnostics
|
January 2005 |
£1495 |
48.3 % |
Survey of Private Companies Active in CNS & PNS Drug R&D, A
|
January 2006 |
£1045 |
48 % |
Clinical Trials of Drugs and Biopharmaceuticals
|
September 2005 |
£99 |
48 % |
The Future of Metabolomics
Building competitive advantage in drug discovery, clinical development and diagnostics
|
August 2006 |
£1495 |
47.5 % |
Survey of Private Companies Active in Alzheimer's Drug R&D; A
|
January 2006 |
£415 |
47.5 % |
New Drug Development
A Regulatory Overview
|
December 2004 |
£85 |
47.5 % |
New Directions in Monoclonal Antibodies
Technologies, Markets, Competition
|
October 2004 |
£1950 |
47.5 % |
Survey of Private Companies Active in Pain Drug R&D; A
|
January 2006 |
£415 |
47.5 % |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
46.5 % |
Commercial Opportunities from Biomarkers
Transforming drug discovery, clinical development and molecular diagnostic
|
May 2006 |
£1495 |
46 % |
Emerging Pharmaceutical Markets
Potential & Problems
|
September 2000 |
£195 |
45 % |
Project Management for the Pharmaceutical Industry
|
September 2004 |
£75 |
44.5 % |
Female Sexual Dysfunction
Prescription Drug Pipeline Overview 2007
|
July 2007 |
£2000 |
44 % |
China Pharmaceuticals Guide
New Policy and Regulation
|
June 2000 |
£200 |
44 % |
Drug Discovery
Current trends and future prospects
|
February 2001 |
£300 |
43.5 % |
U.S. Market for Gastrointestinal Pharmaceuticals
|
September 2005 |
£2255 |
43 % |
Cancer Biomarkers
Enhancing diagnostic, therapeutic and developmental strategies
|
May 2006 |
£2195 |
42.5 % |
Nutraceuticals and Dietary Supplements Markets
|
September 2007 |
£1690 |
41 % |
Drug-Device Combinations
|
June 2005 |
£2255 |
41 % |
Pharmaceutical Packaging Handbook
|
September 2007 |
£130 |
41 % |
Pipeline Insight: Depression
Novel drugs to grow third-line market
|
March 2007 |
£6000 |
41 % |
Stakeholder Insight: Cognitive Impairment in Schizoaffective Disorder
Inevitable or Treatable?
|
October 2005 |
£8695 |
40.5 % |
Pricing and Reimbursement in the US
Innovation and robust pharmacoeconomic analysis are ke
|
June 2006 |
£6495 |
39.5 % |
Model Animal Systems
Emerging Applications and Commercial Opportunities in Drug Discovery and Development
|
June 2004 |
£1946 |
39.5 % |
Analytical Tool: Current & Future Lung Cancer Therapeutics
|
May 2007 |
£2105 |
39.5 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£6000 |
39 % |
Antibody Drug Target Atlas in Oncology
|
June 2007 |
£2330 |
38.5 % |
Health Economics in the Drug Life Cycle
Achieving success in drug discovery, development, reimbursement and marketing
|
January 2003 |
£695 |
38.5 % |
Incyte Corporation
Premium Company Profile
|
April 2008 |
£265 |
38.5 % |
Pharmaceutical and healthcare market in Poland 2005
|
July 2005 |
£985 |
38 % |
Nanotechnology
Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics
|
January 2008 |
£1995 |
38 % |
Early Stage and Discovery Deals
Strategy, Structure and Payment Terms 2nd Edition
|
January 2007 |
£1350 |
37.5 % |
Drug Development Programme Management
|
October 2000 |
£140 |
37.5 % |
Drug Delivery: Principles and Applications
|
May 2005 |
£61.5 |
37.5 % |
The Diabetes Market Outlook
Market analysis of future growth and leading players by sector
|
January 2005 |
£1495 |
37.5 % |
Global Markets for Antifungal Agents
|
March 2007 |
£2410 |
37.5 % |
Indian Medical Market Report
2005
|
May 2005 |
£1110 |
37 % |
Adverse Event Reporting and Pharmacovigilance
Making Drug Safety Happen
|
April 2005 |
£2500 |
37 % |
New Developments in Insulin Delivery Systems (2006)
|
June 2006 |
£495 |
37 % |
Worldwide Pharmaceutical Regulation Series
2002
|
December 2002 |
£280 |
37 % |
Who's Developing What in New Cancer Drugs 2005?
|
September 2005 |
£495 |
37 % |
Generic Drug Product Development: International Regulatory Requirements
|
August 2007 |
£115 |
37 % |
Spain Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
The U.S. Biochip & Equipment Market & Business - 2003 Edition
Technology Trends, Market & Business Trends, Sales, and Distribution
|
July 2001 |
£545 |
36.5 % |
Innovation in Drug Delivery
The future of nanotechnology and non-invasive protein delivery
|
November 2006 |
£1495 |
36.5 % |
Netherlands Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Netherlands Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Optimizing Targeted Treatment in Cancer
Negotiating the Challenges to Success
|
September 2005 |
£1000 |
36.5 % |
Spain Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Central and Core Laboratories
|
October 2007 |
£995 |
36.5 % |
China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Pipeline Insight: HIV
Extending treatment options
|
September 2006 |
£6000 |
36.5 % |
Biomarkers in Clinical Development
Implications for Personalized Medicine and Streamlining R&D
|
March 2005 |
£1950 |
36.5 % |
Japan Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Analytical Tool: Protein Kinase Inhibitors in Oncology
|
February 2006 |
£2105 |
36.5 % |
Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Japan Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Italy Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Italy Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Brazil Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Brazil Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36.5 % |
Innovations in Diagnostics
|
September 2006 |
£1495 |
36 % |
South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36 % |
South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36 % |
UK Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36 % |
UK Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1515 |
36 % |
Industrialization of Drug Discovery
|
May 2005 |
£80 |
36 % |
Biomarkers
The Expanding Global Market
|
November 2007 |
£2410 |
35.5 % |
Competitor Analysis: Biogenerics
|
June 2006 |
£526 |
35.5 % |
Epix Pharmaceuticals Inc
Premium Company Profile
|
January 2008 |
£265 |
35.5 % |
Biogenerics
Competitor Analysis
|
June 2006 |
£526 |
35.5 % |
Drug Delivery Companies Report, The
Autumn/Winter 2004
|
September 2004 |
£185 |
35.5 % |
Opportunities in Drug Delivery
Identifying hot technologies, companies and markets
|
September 2003 |
£400 |
35 % |
China Medical Sales Channel Report, 2006-2007
|
March 2007 |
£445 |
35 % |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
35 % |
Live-Licensing & In-life Testing
R&D Processes and Regulation for New Drugs, 2008-2020
|
January 2008 |
£1499 |
35 % |
Analytical Tool: Competitive Outlook on HCV
|
July 2004 |
£1015 |
35 % |
Commercial & Pipeline Insight: Hospital Antibacterials A market beyond MRSA
|
August 2007 |
£8010 |
35 % |
Drug Delivery in Central Nervous System Disorders
Technologies, Markets and Companies
|
March 2008 |
£1240 |
34.5 % |
Pipeline Insight: Hepatitis C
Protease inhibitors to drive market expansion
|
June 2006 |
£6495 |
34.5 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£3510 |
34.5 % |
Therapeutics for Inflammatory Diseases
Current Challenges and Future Market
|
March 2006 |
£2410 |
34.5 % |
Drug Discovery Strategies and Methods
|
November 2003 |
£100 |
34 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
|
July 2007 |
£3510 |
34 % |
New Drug Futures: Vaccines Chapter
|
May 2006 |
£695 |
34 % |
Stakeholder Opinions: Nosocomial Infections
The need for new gram-negative drugs
|
March 2007 |
£2000 |
34 % |
Neurogen Corporation
Premium Company Profile
|
January 2008 |
£265 |
34 % |
Stability-indicating HPLC Methods for Drug Analysis
3rd Edition
|
January 2008 |
£150 |
34 % |
Ambulatory Infusion Pumps in Pain Management
A Market Briefing
|
August 2004 |
£450 |
33.5 % |
India Drug Delivery Devices Industry Report
Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Infusion Systems, Inhalation Systems and Needle Free Injections Medical Equipment and Supplies
|
April 2008 |
£1515 |
33.5 % |
Molecular Nanotechnology in Medicine
A Market Briefing
|
September 2004 |
£450 |
33.5 % |
Inhaled Insulin
A Market Briefing
|
July 2004 |
£450 |
33.5 % |
Pharmaceutical Regulatory Industry
|
January 2006 |
£2410 |
33.5 % |
Stakeholder Insight
Prostate Cancer - Hormone-refractory patients still waiting for treatment breakthroughs
|
December 2007 |
£7600 |
33.5 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£2340 |
33 % |
Pipeline Insight: Schizophrenia
|
July 2006 |
£6330 |
33 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£2340 |
33 % |
Cancer Vaccine Developments to 2011
|
September 2007 |
£1296 |
33 % |
Biomarkers
Technologies, Markets and Companies
|
March 2008 |
£1515 |
33 % |
Merck Druggernaut; The
The Inside Story of a Pharmaceutical Giant
|
March 2005 |
£11.99 |
33 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£3510 |
33 % |
US Launch
Phase IIIA, Phase IIIB and Launch Year Brand Commercialization
|
December 2006 |
£3885 |
32.5 % |
Immunotherapy of Cancer
|
March 2007 |
£2410 |
32.5 % |
United States Drug Delivery Devices Medical Equipment Industry Report
Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Infusion Systems, Inhalation Systems and Needle Free Injections Medical Equipment and Supplies
|
April 2008 |
£1515 |
32.5 % |
The Global Pain Therapeutics Market
Market Analysis, R&D Pipelines and Competitive Landscape
|
October 2007 |
£1515 |
32.5 % |
Drug Delivery Markets, Vol II
Implantable Injectable
|
February 2007 |
£1260 |
32.2 % |
New Drug Approval in the United States
|
November 2002 |
£80 |
32 % |
Novel Targets in Drug Discovery
A new era in therapy
|
April 2004 |
£595 |
32 % |
Array Biopharma Inc.
Premium Company Profile
|
December 2007 |
£265 |
32 % |
Nanotechnology in Life Science Applications
|
October 2005 |
£2255 |
32 % |
Pricing & Reimbursement in Europe
Can the drive for cost effectiveness overcome cost containment?
|
October 2006 |
£6000 |
32 % |
Pharmaceutical Stress Testing
Predicting Drug Degradation
|
June 2005 |
£130 |
32 % |
Leading Pharmaceutical Innovation
How to Predict Blockbuster Products
|
January 2004 |
£38.5 |
31.5 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£215 |
31.5 % |
The Medical Device Market: USA
|
March 2006 |
£695 |
31.5 % |
The Pharmaceutical Market: Philippines
|
March 2007 |
£595 |
31.5 % |
Protein Formulation and Delivery, 2nd edition
|
September 2007 |
£115 |
31.5 % |
2015: Strategic Considerations for the U.S. Pharmaceutical Industry
|
February 2005 |
£1810 |
31.5 % |
The Medical Device Market: USA
|
May 2006 |
£595 |
31.5 % |
Lexicon Pharmaceuticals Inc
Premium Company Profile
|
April 2008 |
£265 |
31.5 % |
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit
|
July 2007 |
£6000 |
31.5 % |
Pipeline Insight: Anxiety Disorders
A decade of declining revenues
|
March 2006 |
£6495 |
31.5 % |
Current and Future Therapies for Lung Cancer
A Therapeutic & Competitive Insight
|
March 2006 |
£1325 |
31 % |
Blockbuster Pharmaceutical Launches
Establishing Market Leadership
|
May 2006 |
£1665 |
31 % |
Neuroprotection in Stroke
Protecting the Brain Sells
|
January 2005 |
£1000 |
31 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£4715 |
31 % |
Bioinformatics Opportunities
Business models, trends and future challenges
|
May 2004 |
£2500 |
31 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
31 % |
New Drug Futures: Cardiovascular Chapter
|
May 2006 |
£695 |
31 % |
Indian Pharmaceutical Industry
|
July 2008 |
£1715 |
30.5 % |
Biogenerics, The World Market
Biosimilars and Follow-On Biologics at a Crossroads
|
April 2008 |
£1765 |
30.5 % |
Interstitial Cystitis
Few Treatments, Poor Outcome
|
April 2006 |
£4340 |
30.5 % |
Personalized Medicine
Scientific & Commercial Aspects
|
March 2008 |
£1740 |
30.5 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
30.5 % |
Ibuprofen
A Critical Bibliographic Review
|
May 1999 |
£115 |
30.5 % |
Pipeline Insight: Antihypertensives
Together We Stand, Divided We Fail
|
August 2004 |
£6000 |
30.5 % |
Non-Small Cell Lung Cancer Drug Pipeline Update 2007
|
April 2007 |
£1015 |
30.5 % |
Premium Company Profile: Cardiome Pharma Corp.
|
November 2007 |
£265 |
30.5 % |
Stakeholder Opinions: Alpha 1 Antitrypsin Deficiency
|
January 1970 |
£2000 |
30.5 % |
Pharmaceutical Discovery & Development Report
|
June 2004 |
£185 |
30.5 % |
Stakeholder Insight: Supportive Care in Cancer Treatment
Some first-generation products proving difficult to dislodge
|
October 2006 |
£8000 |
30 % |
Stakeholder Opinions: Acute Leukemias
Persistent unmet needs confer significant commercial opportunity
|
April 2006 |
£2170 |
30 % |
Pipeline Insight: Osteoarthritis
The Wait for a DMOAD Continues
|
November 2006 |
£6000 |
30 % |
Europe IT Spending on Business Intelligence to 2012 Pharmaceutical Technology
|
April 2007 |
£695 |
30 % |
Pharmaceutical Biotechnology: Fundamentals and Applications
Third Edition
|
October 2007 |
£115 |
30 % |
Cytokinetics Inc: Premium Company Profile
|
February 2008 |
£265 |
30 % |
The Pharmaceutical Market: Bulgaria
|
September 2007 |
£595 |
30 % |
Central Nervous System - Pain Drug Pipeline Report
|
February 2008 |
£1495 |
29.5 % |
Central Nervous System - Neuropathy Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Central Nervous System - Seizures Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Central Nervous System - Schizophrenia Drug Pipeline Report
|
February 2008 |
£1495 |
29.5 % |
Digestive System - Indigestion Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Digestive System - Diarrhea Drug Pipeline Report
|
February 2008 |
£1495 |
29.5 % |
Digestive System - Ulcers Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
World Cancer Market Yearbook 2005
|
December 2005 |
£495 |
29.5 % |
Infections - AIDS HIV Drug Pipeline Report
|
February 2008 |
£1495 |
29.5 % |
Digestive System - Constipation Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Digestive System - Acidity Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Dental - Caries Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Dermatology - Acne Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Dermatology - Burns Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Dermatology - Eczema Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Central Nervous System - Stroke Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Cardiovascular and Circulatory System - Stroke Drug Pipeline Report
|
February 2008 |
£1495 |
29.5 % |
Blood and Lymphatic System - Anemia Drug Pipeline Report
|
February 2008 |
£1495 |
29.5 % |
Blood and Lymphatic System - Hyperlipemia Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Biomarkers & Related Tests for Molecular Diagnostics & Pharma/ Biotech R&D
Companies, Products & Worldwide Market, 2004-2009
|
July 2005 |
£940 |
29.5 % |
Blood and Lymphatic System - Thromboembolism Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Autoimmune and Inflammation - Lupus Drug Pipeline Report
|
February 2008 |
£1495 |
29.5 % |
Infections - Fever Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Canada Pharmaceuticals & Healthcare
|
September 2006 |
£395 |
29.5 % |
Autoimmune and Inflammation - Allergy Drug Pipeline Report
|
February 2008 |
£1495 |
29.5 % |
Autoimmune and Inflammation - Arthritis Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Autoimmune and Inflammation - Inflammation - Drug Pipeline Report
|
February 2008 |
£1495 |
29.5 % |
Cardiovascular and Circulatory System - Angina Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Cardiovascular and Circulatory System - Arrhythmiasis Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Central Nervous System - Dementia Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Central Nervous System - Depression Drug Pipeline Report
|
February 2008 |
£1495 |
29.5 % |
Central Nervous System - Epilepsy Drug Pipeline Report
|
February 2008 |
£995 |
29.5 % |
Central Nervous System - Headache Drug Pipeline Report
|
February 2008 |
£995 |
